|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Jazz Pharmaceuticals plc
| | | Phone: | (650) 496-3777 | Fax: | (650) 496-3781 | Year Established: | 2003 | Ticker: | JAZZ | Exchange: | NASDAQ | Main Contact: | Daniel N. Swisher, Jr., President & COO | | Other Contacts: | Bruce C. Cozadd, Chairman & CEO Robert McKague, Senior VP, Associate General Counsel Matthew Young, Executive VP & CFO Paul Treacy, Senior VP, Technical Operations Michael P. Miller, Senior VP, US Commercial Suzanne Sawochka Hooper, Executive VP & General Cuonsel
| | Company Description | Jazz Pharmaceuticals is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi) and Defitelio® (defibrotide sodium) in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S. | |
|
|
|
|
|